Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Nirav N. Shah, Zulfa Omer, Graham P. Collins, Francesco Forconi, Alexey Danilov, John C. Byrd, Dima El-Sharkawi, Emma Searle, Alvaro J Alencar, Shuo Ma, Sarah Injac, Talha Munir

Blood (2024) 144 (Supplement 1): 884.

https://doi.org/10.1182/blood-2024-194839

Published: 2024

Journal Articles

Single-Cell Transcriptional Characteristics of the Unresponsive Cluster Surviving Anergy in IGHV1-69 CLL

Stuart Lanham, Luis Del Rio Fernandez, Stefano de Pretis, Joshua Grant, Isla Henderson, Benjamin Sale, Lauren Griffith, David Dutton, Giovanni Tonon, Freda K. Stevenson, Francesco Forconi

Blood (2024) 144 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2024-210464

Published: 2024

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Time for a new prognostic score in CLL?

Francesco Forconi

Blood (2024) 143 (25): 2561–2562.

https://doi.org/10.1182/blood.2024024877

Published: 2024

Journal Articles

The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells

Freda K. Stevenson, Francesco Forconi

Blood (2024) 143 (12): 1091–1100.

https://doi.org/10.1182/blood.2023022703

Published: 2024

Journal Articles

Analysis of Single B Cells Reveals a Double Drive of Endocytosis and Transcriptional Downregulation Acting on the CLL B-Cell Receptor In Vivo

Stuart Lanham, Luis Del Rio Fernandez, Joshua Grant, Isla Henderson, Ben Sale, Dean J. Bryant, Lauren Griffith, Alberto Orfao, Freda K. Stevenson, Francesco Forconi

Blood (2023) 142 (Supplement 1): 6508.

https://doi.org/10.1182/blood-2023-188571

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

The Proliferative History Index, Epicmit, Derived from Genome-Wide Epigenomic Profiling, Is a Key Driver of Clinical Survival in Splenic Marginal Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4370.

https://doi.org/10.1182/blood-2023-174481

Published: 2023

Journal Articles

Oligomannose-Type Glycans in the Antigen Binding Site Identify Origin and Prognosis of Diffuse Large B Cell Lymphoma

Dylan J. Tatterton, Benjamin Sale, Joel Allen, Maddy L. Newby, Giorgia Chiodin, Patrick J. Duriez, John Butler, Katy J. McCann, David W. Scott, Ryan Morin, Andrew S. Davies, Dean J. Bryant, Freda K. Stevenson, Max Crispin, Francesco Forconi

Blood (2023) 142 (Supplement 1): 428.

https://doi.org/10.1182/blood-2023-188721

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Emma Searle, Francesco Forconi, Kim Linton, Alexey Danilov, Pam McKay, David Lewis, Dima El-Sharkawi, Mary Gleeson, John Riches, Sarah G. Injac, Ted Shih, Srinand Nandakumar, May Tan, Ganesh Cherala, Erin Meredith, Graham P. Collins

Blood (2023) 142 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2023-179508

Published: 2023

Journal Articles

Selinexor Enhances Natural Killer Cell Function Against Multiple Myeloma Cells

Jack G Fisher, Amber DP Doyle, Lara V Graham, Francesco Forconi, Mark S Cragg, Christopher J Walker, Salim I Khakoo, Matthew D Blunt

Blood (2023) 142 (Supplement 1): 6599.

https://doi.org/10.1182/blood-2023-179744

Published: 2023

Journal Articles

EMT-like Activation in CLL Provides Novel Therapeutic Target

Charlott Repschlaeger, Mariette Odabashian, Filomena Spada, Zamzam Almutairi, John G. Gribben, Francesco Forconi, Emre Sayan, Alexessander Couto Alves, Charline Giroud, Oleg Fedorov, Marina Kriajevskaia, Sergey Krysov

Blood (2022) 140 (Supplement 1): 12375–12376.

https://doi.org/10.1182/blood-2022-162696

Published: 2022

Journal Articles

DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1

Giorgia Chiodin, Dylan Tatterton, Patrick J Duriez, Ayse Ertay, Philip J Rock, Benjamin Sale, Stuart Lanham, Luis Del Rio, Carl Figdor, Richard Burack, Freda K Stevenson, Francesco Forconi

Blood (2022) 140 (Supplement 1): 6460–6461.

https://doi.org/10.1182/blood-2022-169647

Published: 2022

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment

Zhenghao Chen, Helga Simon-Molas, Gaspard Cretenet, Beatriz Valle-Argos, Lindsay D. Smith, Francesco Forconi, Bauke V. Schomakers, Michel van Weeghel, Dean J. Bryant, Jaco A. C. van Bruggen, Fleur S. Peters, Jeffrey C. Rathmell, Gerritje J. W. van der Windt, Arnon P. Kater, Graham Packham, Eric Eldering

Blood (2022) 140 (6): 630–643.

https://doi.org/10.1182/blood.2021013990

Published: 2022

Includes: Supplemental data

Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2021-152167

Published: 2021

Journal Articles

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Jack Fisher, Christopher J. Walker, Peter Johnson, Mark S Cragg, Francesco Forconi, Yosef Landesman, Salim I Khakoo, Matthew D Blunt

Blood (2021) 138 (Supplement 1): 2411.

https://doi.org/10.1182/blood-2021-144836

Published: 2021

Journal Articles

Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance

Zhenghao Chen, Helga Simon-Molas, Gaspard Cretenet, Beatriz Valle-Argos, Francesco Forconi, Bauke V Schomakers, Michel van Weeghel, Dean Bryant, Jaco A. C. Van Bruggen, Fleur Peters, Gerritje J. W. van der Windt, Arnon P. Kater, Graham Packham, Eric Eldering

Blood (2021) 138 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2021-150236

Published: 2021

NARROW

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Single-Cell Transcriptional Characteristics of the Unresponsive Cluster Surviving Anergy in IGHV1-69 CLL

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Time for a new prognostic score in CLL?

The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells

Analysis of Single B Cells Reveals a Double Drive of Endocytosis and Transcriptional Downregulation Acting on the CLL B-Cell Receptor In Vivo

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

The Proliferative History Index, Epicmit, Derived from Genome-Wide Epigenomic Profiling, Is a Key Driver of Clinical Survival in Splenic Marginal Zone Lymphoma

Oligomannose-Type Glycans in the Antigen Binding Site Identify Origin and Prognosis of Diffuse Large B Cell Lymphoma

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Selinexor Enhances Natural Killer Cell Function Against Multiple Myeloma Cells

EMT-like Activation in CLL Provides Novel Therapeutic Target

DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only